vs
MARAVAI LIFESCIENCES HOLDINGS, INC.（MRVI）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是MARAVAI LIFESCIENCES HOLDINGS, INC.的1.4倍（$71.1M vs $49.9M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -71.6%，领先73.6%），RE/MAX Holdings, Inc.同比增速更快（-1.8% vs -11.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-24.9M），过去两年RE/MAX Holdings, Inc.的营收复合增速更高（-4.7% vs -11.9%）
Maravai生命科学控股是一家全球化生命科学企业，专注于开发供应关键试剂、诊断产品及技术解决方案，服务于生物制药研发、药物开发、临床诊断及细胞和基因疗法制造领域，客户覆盖全球相关科研、医疗和企业机构。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
MRVI vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.4倍
$49.9M
营收增速更快
RMAX
高出10.0%
-11.8%
净利率更高
RMAX
高出73.6%
-71.6%
自由现金流更多
RMAX
多$58.4M
$-24.9M
两年增速更快
RMAX
近两年复合增速
-11.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $49.9M | $71.1M |
| 净利润 | $-35.7M | $1.4M |
| 毛利率 | 25.8% | — |
| 营业利润率 | -117.9% | 13.1% |
| 净利率 | -71.6% | 2.0% |
| 营收同比 | -11.8% | -1.8% |
| 净利润同比 | -37.7% | -75.2% |
| 每股收益（稀释后） | $-0.24 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRVIRMAX
| Q4 25 | $49.9M | $71.1M | ||
| Q3 25 | $41.6M | $73.2M | ||
| Q2 25 | $47.4M | $72.8M | ||
| Q1 25 | $46.9M | $74.5M | ||
| Q4 24 | $56.6M | $72.5M | ||
| Q3 24 | $69.0M | $78.5M | ||
| Q2 24 | $69.4M | $78.5M | ||
| Q1 24 | $64.2M | $78.3M |
净利润MRVIRMAX
| Q4 25 | $-35.7M | $1.4M | ||
| Q3 25 | $-25.6M | $4.0M | ||
| Q2 25 | $-39.6M | $4.7M | ||
| Q1 25 | $-29.9M | $-2.0M | ||
| Q4 24 | $-25.9M | $5.8M | ||
| Q3 24 | $-97.1M | $966.0K | ||
| Q2 24 | $-9.8M | $3.7M | ||
| Q1 24 | $-12.1M | $-3.4M |
毛利率MRVIRMAX
| Q4 25 | 25.8% | — | ||
| Q3 25 | 13.6% | — | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 46.7% | — | ||
| Q2 24 | 44.4% | — | ||
| Q1 24 | 40.3% | — |
营业利润率MRVIRMAX
| Q4 25 | -117.9% | 13.1% | ||
| Q3 25 | -98.6% | 25.0% | ||
| Q2 25 | -139.8% | 19.3% | ||
| Q1 25 | -104.9% | 7.2% | ||
| Q4 24 | -66.7% | 5.9% | ||
| Q3 24 | -239.9% | 19.4% | ||
| Q2 24 | -19.4% | 20.6% | ||
| Q1 24 | -29.4% | 5.8% |
净利率MRVIRMAX
| Q4 25 | -71.6% | 2.0% | ||
| Q3 25 | -61.4% | 5.4% | ||
| Q2 25 | -83.5% | 6.4% | ||
| Q1 25 | -63.9% | -2.6% | ||
| Q4 24 | -45.8% | 8.0% | ||
| Q3 24 | -140.6% | 1.2% | ||
| Q2 24 | -14.1% | 4.7% | ||
| Q1 24 | -18.8% | -4.3% |
每股收益（稀释后）MRVIRMAX
| Q4 25 | $-0.24 | — | ||
| Q3 25 | $-0.18 | — | ||
| Q2 25 | $-0.27 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.21 | — | ||
| Q3 24 | $-0.68 | — | ||
| Q2 24 | $-0.07 | — | ||
| Q1 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $216.9M | $118.7M |
| 总债务越低越好 | $291.8M | $432.2M |
| 股东权益账面价值 | $212.4M | $452.4M |
| 总资产 | $770.6M | $582.5M |
| 负债/权益比越低杠杆越低 | 1.37× | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资MRVIRMAX
| Q4 25 | $216.9M | $118.7M | ||
| Q3 25 | $243.6M | $107.5M | ||
| Q2 25 | $269.9M | $94.3M | ||
| Q1 25 | $285.1M | $89.1M | ||
| Q4 24 | $322.4M | $96.6M | ||
| Q3 24 | $578.2M | $83.8M | ||
| Q2 24 | $573.2M | $66.1M | ||
| Q1 24 | $561.7M | $82.1M |
总债务MRVIRMAX
| Q4 25 | $291.8M | $432.2M | ||
| Q3 25 | $292.8M | $433.3M | ||
| Q2 25 | $293.9M | $434.4M | ||
| Q1 25 | $294.9M | $435.3M | ||
| Q4 24 | $295.9M | $436.2M | ||
| Q3 24 | $521.7M | $437.2M | ||
| Q2 24 | $522.5M | $438.1M | ||
| Q1 24 | $523.3M | $439.0M |
股东权益MRVIRMAX
| Q4 25 | $212.4M | $452.4M | ||
| Q3 25 | $245.4M | $448.1M | ||
| Q2 25 | $265.9M | $442.4M | ||
| Q1 25 | $300.6M | $433.5M | ||
| Q4 24 | $325.3M | $429.5M | ||
| Q3 24 | $344.9M | $423.1M | ||
| Q2 24 | $434.7M | $418.4M | ||
| Q1 24 | $410.7M | $412.0M |
总资产MRVIRMAX
| Q4 25 | $770.6M | $582.5M | ||
| Q3 25 | $849.2M | $582.2M | ||
| Q2 25 | $897.0M | $574.8M | ||
| Q1 25 | $959.8M | $571.4M | ||
| Q4 24 | $1.0B | $581.6M | ||
| Q3 24 | $1.3B | $578.6M | ||
| Q2 24 | $1.4B | $571.4M | ||
| Q1 24 | $1.4B | $566.7M |
负债/权益比MRVIRMAX
| Q4 25 | 1.37× | 0.96× | ||
| Q3 25 | 1.19× | 0.97× | ||
| Q2 25 | 1.11× | 0.98× | ||
| Q1 25 | 0.98× | 1.00× | ||
| Q4 24 | 0.91× | 1.02× | ||
| Q3 24 | 1.51× | 1.03× | ||
| Q2 24 | 1.20× | 1.05× | ||
| Q1 24 | 1.27× | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.8M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-24.9M | $33.5M |
| 自由现金流率自由现金流/营收 | -49.9% | 47.1% |
| 资本支出强度资本支出/营收 | 4.2% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-70.7M | $56.8M |
8季度趋势，按日历期对齐
经营现金流MRVIRMAX
| Q4 25 | $-22.8M | $40.9M | ||
| Q3 25 | $-15.2M | $17.7M | ||
| Q2 25 | $-10.3M | $4.6M | ||
| Q1 25 | $-9.4M | $5.7M | ||
| Q4 24 | $-14.6M | $59.7M | ||
| Q3 24 | $13.1M | $17.6M | ||
| Q2 24 | $17.4M | $15.9M | ||
| Q1 24 | $-8.5M | $9.4M |
自由现金流MRVIRMAX
| Q4 25 | $-24.9M | $33.5M | ||
| Q3 25 | $-18.1M | $16.4M | ||
| Q2 25 | $-13.1M | $2.9M | ||
| Q1 25 | $-14.6M | $4.0M | ||
| Q4 24 | $-20.5M | $53.0M | ||
| Q3 24 | $4.5M | $16.3M | ||
| Q2 24 | $7.9M | $14.0M | ||
| Q1 24 | $-14.1M | $6.8M |
自由现金流率MRVIRMAX
| Q4 25 | -49.9% | 47.1% | ||
| Q3 25 | -43.4% | 22.4% | ||
| Q2 25 | -27.7% | 4.0% | ||
| Q1 25 | -31.2% | 5.3% | ||
| Q4 24 | -36.2% | 73.2% | ||
| Q3 24 | 6.6% | 20.8% | ||
| Q2 24 | 11.4% | 17.8% | ||
| Q1 24 | -22.0% | 8.6% |
资本支出强度MRVIRMAX
| Q4 25 | 4.2% | 10.4% | ||
| Q3 25 | 7.0% | 1.8% | ||
| Q2 25 | 6.1% | 2.2% | ||
| Q1 25 | 11.2% | 2.3% | ||
| Q4 24 | 10.3% | 9.1% | ||
| Q3 24 | 12.4% | 1.7% | ||
| Q2 24 | 13.8% | 2.4% | ||
| Q1 24 | 8.8% | 3.3% |
现金转化率MRVIRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRVI
| Cygnus Segment | $27.2M | 54% |
| Other | $18.4M | 37% |
| Shipping And Handling | $4.3M | 9% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
